Upadacitinib tied to fewer colectomies than tofacitinib in ASUC
-
October 16
By week 52, 23% of patients given upadacitinib vs. 43% given tofacitinib had undergone colectomy in a retrospective study of 150 Australian adults.
BROWSE BY TOPICS
Substance use disorders in gastroenterology and hepatology: A practical guide for the general gastroenterologist
-
August 3
-
by Isabelle S. Byers, MD, Michelle Russin, MD, Sasha Deutsch-Link, MD, MSCR
GI and liver complications often bring these patients in first, and the authors say gastroenterologists are well placed to screen and treat.
Bridging the rural divide: Building a motility center in a critical access hospital
-
August 3
-
by Amber Charoen, MD, W. Michael McDonnell, MD, AGAF
“If large urban centers can run comprehensive motility labs, why can't a critical access hospital?”
Is professional coaching worth it? A practical guide for early-career gastroenterologists
-
August 3
-
by Mariam Naveed, MD, FACG, Kathryn E. Hutchins, MD, FACG
Two program directors on why coaching belongs at the start of a GI career, not after something has already gone wrong.
The Latest
Nearly 11,000-patient trial may prompt rethink of 3-year surveillance after adenoma removal
-
by Julia Cipriano
“More than 99% of the patients in this trial did not receive a diagnosis of colorectal cancer within 5 years after polyp removal.”
Upadacitinib tied to fewer colectomies than tofacitinib in ASUC
-
by Doug Brunk
By week 52, 23% of patients given upadacitinib vs. 43% given tofacitinib had undergone colectomy in a retrospective study of 150 Australian adults.
In pooled trials, cold snare EMR cut adverse events but doubled recurrence
-
by Meg Barbor
“Current evidence excludes cold EMR as an adequate technique for advanced adenomas,” the authors wrote.
Dropping age from FIB-4 may simplify MASLD fibrosis screening
-
by Julia Cipriano
Across 938 patients, five age-handling strategies had similar discrimination for fibrosis but traded off sensitivity and specificity differently, investigators reported.
Meta-analysis finds germline variants in 15% of patients with colorectal cancer
-
by Meg Barbor
The yield was 13.0% among patients diagnosed at age 50 or older, and predicted yield of high-penetrance variants stayed above a 5% testing threshold until about age 67.
Esophagus
Liver
Small bowel
Stomach
Obesity
Alcohol-related liver disease
Biliary tract cancer
Colorectal cancer
Esophageal cancer
Liver cancer
Celiac disease
Diarrhea and constipation
Diet and nutrition
Eosinophilic GI diseases
Eosinophilic esophagitis
Hepatic encephalopathy
IBD
Crohn's disease
Ulcerative colitis
IBS
Infections
C. diff
MASLD and MASH
Short bowel syndrome
Pancreatic diseases and conditions
GERD and Barrett’s esophagus
Career & professional development
Diversity, equity, and inclusion
Health, wellness, and burnout
Patient advocacy and equity
Practice management
Coding, coverage, and reimbursement
Technology & innovation
Endoscopy